Recent policies provide detailed instruction to promote the implementation of preferential policies of high-value drugs. Noteworthy policy items include:
- President Xi emphasized promoting a Comprehensive Regulatory System of Healthcare at the second meeting of the Central Leading Committee for Comprehensively Deepening Reform
- State Council released Plans for Deepening Reforms and Opening up in Free Trade Pilot Zones of Fujian, Tianjin, and Guangdong
- SDA and NHC released Announcement Regarding Optimizing Several Issues within the Drug Registration and Approval Process
- NHC released the first Catalog of Rare Diseases and the Working Procedure for the Formulation of the Catalog
The latest issue could be downloaded Here.
